StoneX Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$430K Buy
+2,818
New +$422K 0.02% 635
2026
Q1
Sell
-2,573
Closed -$355K 1156
2025
Q4
$355K Buy
2,573
+342
+15% +$44.8K 0.02% 636
2025
Q3
$286K Buy
2,231
+7
+0.3% +$854 0.01% 717
2025
Q2
$269K Sell
2,224
-1,861
-46% -$210K 0.01% 693
2025
Q1
$466K Buy
4,085
+1,843
+82% +$196K 0.03% 491
2024
Q4
$218K Buy
+2,242
New +$239K 0.01% 724
2024
Q1
Sell
-2,188
Closed -$221K 696
2023
Q4
$221K Sell
2,188
-97
-4% -$9.36K 0.02% 497
2023
Q3
$233K Sell
2,285
-349
-13% -$35.4K 0.03% 479
2023
Q2
$266K Buy
2,634
+270
+11% +$27K 0.03% 442
2023
Q1
$217K Buy
+2,364
New +$206K 0.02% 508
2022
Q3
Sell
-3,439
Closed -$291K 674
2022
Q2
$291K Sell
3,439
-4,012
-54% -$352K 0.04% 426
2022
Q1
$654K Buy
+7,451
New +$645K 0.05% 301
2021
Q4
Sell
-105,169
Closed -$8.6M 597
2021
Q3
$8.6M Buy
+105,169
New +$9.46M 1.24% 14
2017
Q3
Sell
-24,848
Closed -$1.86M 299
2017
Q2
$1.86M Buy
24,848
+10,237
+70% +$726K 0.58% 44
2017
Q1
$954K Sell
14,611
-136
-0.9% -$9.06K 2.13% 14
2016
Q4
$963K Buy
+14,747
New +$957K 1.68% 17

Other funds holding NVS

StoneX Group's NVS Position: Q2 2026 in Review

StoneX Group opened a new position in Novartis (NVS) in Q2 2026: 2,818 shares worth $430K. The stake represents 0.02% of the portfolio and ranks #635 among its holdings. This is a return to the name: StoneX Group previously reported a position in NVS as recently as Q4 2025.

StoneX Group first reported a position in NVS in Q4 2016 and has held it in 16 quarters since. The position peaked at $8.6M in Q3 2021. 1,618 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • StoneX Group held 2,818 shares of Novartis worth $430K as of Q2 2026.
  • Novartis was a new StoneX Group position in Q2 2026.
  • Novartis made up 0.02% of StoneX Group's portfolio in Q2 2026, its #635 holding.
  • StoneX Group first reported a position in Novartis in Q4 2016 and has held it in 16 quarters since.
  • StoneX Group's Novartis position peaked at $8.6M in Q3 2021.
  • 1,618 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on StoneX Group's 13F filing for Q2 2026, filed 12 Aug 2026.